Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2007 by Dana-Farber Cancer Institute.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Massachusetts General Hospital
Information provided by:
Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00280930
First received: January 23, 2006
Last updated: January 18, 2007
Last verified: January 2007

January 23, 2006
January 18, 2007
October 2005
Not Provided
To determine the proportion of women with breast density of > grade 4 who have a decrease in breast density of at least one grade after treatment with letrozole for one year.
Same as current
Complete list of historical versions of study NCT00280930 on ClinicalTrials.gov Archive Site
  • To determine if the decrease in breast density grade is sustained one year after cessation of therapy
  • to determine if there is a correlation between plasma estrogen profile and breast density at baseline
  • to determine the percentage of subjects with breast tissue hyperplasia and atypical hyperplasia before and after therapy
  • to assess change in estrogen profile from baseline and at 1 year and 1 year after cessation of therapy
  • to assess the general safety of the utilization of letrozole in healthy post-menopausal women for one year
  • to compare the effects on menopause-specific quality of life.
Same as current
Not Provided
Not Provided
 
Letrozole in Postmenopausal Women at Increased Risk for Breast Cancer
A Randomized Feasibility Study of Letrozole in Postmenopausal Women at Increased Risk for Development of Breast Cancer as Evidenced by High Breast Density

The purpose of this study to see what happens to breast density in healthy postmenopausal women after treatment with letrozole in one year, compared with treatment with placebo for one year. Other goals of the study include determining if there is a connection between estrogen level and breast density for women in the study and collecting information about the quality of life of those taking part in the study.

  • Patients will be randomized into one of two study groups. Group 1 will receive letrozole and Group 2 will receive placebo. This is a double-blind trial so neither the patient or the doctor will know what treatment group they are assigned to.
  • If the patient is in Group 1 they will take letrozole tablets orally once a day with food for one year. Patients in Group 2 will take a placebo tablet orally once a day with food for one year.
  • Patients in both groups will also be given calcium tablets (500mg) and vitamin D tablets (400IU) once a day for one year.
  • After the initial screening visits, the patient will return to the clinic at 3, 6, 9 and 12 months (a total of up to 6 visits in the first year). There will also be two follow-up visits at 18 and 24 months. For the 3, 9 and 18 month visits, telephone contact instead of a clinic visit is allowed.
  • The following tests and procedures will be performed during these visits:

evaluation of side effects; routine blood tests(6, 12, and 24 month visits); urine sample (6 and 12 month visits); complete physical exam including breast exam (12 and 24 month visits); mammogram (12 and 24 month visits); bone marrow density x-ray test (12 and 24 month visits); standard x-rays of the lower back and chest (12 month visit); and a questionnaire about how the patient is feeling (12 and 24 month visits).

  • The length of participation in this study is for 1 year of study treatment followed by 1 year of follow-up.
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Prevention
  • Post-Menopausal
  • Breast Cancer
Drug: Letrozole
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
60
Not Provided
Not Provided

Inclusion Criteria:

  • Postmenopausal status defined as: women >55 years of age-no spontaneous menses for at least 12 months; in women < 55 years-no spontaneous menses within the past 12 months and with an FSH level >34.4 IU/I; bilateral oophorectomy
  • If subject had prior invasive breast cancer it must have been surgically removed at the time of orginal diagnosis with no evidence of metastases and the primary tumor may be receptive negative, positive or equivocal
  • Baseline mammogram (within 6 months) indicating mammographic density occupying >25% (grade 4/5, 5/6 or 6/6) of the breast tissue
  • Baseline breast examination demonstrating no clinical evidence of breast cancer
  • Acceptable quality DEXA of the L2-L4 postero-anterior (PA) spine and hup must be performed 6 months of randomization
  • Subject is willing and able to complete the quality of life questionnaire in either English or French

Exclusion Criteria:

  • Mammogram suspicious for breast cancer (unless subsequently ruled out)
  • Patient's with prior malignancies are eligible unless they have metastatic disease
  • Uncontrolled metabolic or endocrine disease, cardiovascular disease or malabsorption syndrome
  • Current chemotherapy or immunotherapy
  • Hormone replacement therapy or Evista (raloxifene) discontinued less than three months before baseline mammogram
  • Tamoxifen therapy discontinued less than six months prior to randomization
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00280930
05-183, NCIC CTG MAP.1
Not Provided
Not Provided
Dana-Farber Cancer Institute
  • Beth Israel Deaconess Medical Center
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
Principal Investigator: Paul Goss, MD, PhD Massachusetts General Hospital
Dana-Farber Cancer Institute
January 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP